Look out for XF-73 Destiny

Destiny Pharma (LON: DEST) expects to report on the study results of the phase 2b clinical study on the use of XF-73 nasal gel for the prevention of post-surgical infections by the end of March. finnCap believes that positive news would increase the broker’s valuation of Destiny by 80p a share.

Destiny is a developer of antimicrobial drugs. The main focus has been on XF-73, which is used to treat post-surgical infections, such as MRSA. There are also other potential uses of the XF platform, including a collaboration with SporeGen for the prevention of Covid-19 and other respiratory viral infections.

The phase 2b trial has enrolled 125 patients undergoing heart surgery in the US and Europe. XF-73 has been shown to be safe and fast. Importantly, it does not appear to generate antimicrobial resistance. The potential addressable market in the US is estimated to be $3bn a year – based on 15 million surgical patients.

An evaluation agreement for a dermal version of XF-73 has been signed with the US National Institute of Allergy and Infectious Diseases.

Finances

Destiny has the cash it requires in the medium-term. In November, Destiny raised £10.4m from a placing and open offer at 65p a share. Since then, Destiny has acquired NTCD-M3, which is a C.diff treatment. There was already cash in the bank and there should still be net cash of at least £5m at the end of 2021.

If Destiny secures a partner for one of its treatments, there could be an initial cash injection with more to come over the long-term.

The 2020 results are due to be published on 14 April.

Valuation

finnCap has a target price of 300p a share and that could rise to 380p a share with positive news about the XF-73 clinical trial.

So far this year, the share price has more than doubled to 159.5p. That leaves plenty of upside, particularly if the trial news is good.

Previous articleNew Aquis admission: Samarkand
Next articleEntain records profit as online gaming jumps during pandemic
Andrew Hore
Andrew Hore is the publisher of AIM Journal, which is an online monthly publication covering the Alternative Investment Market.